Is SXTP or ATHX more profitable?

Athersys has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals -574.91% N/A -131.48% Athersys N/A N/A -223.03%

Which has preferable valuation and earnings, ATHX or VCNX?

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Vaccinex $388K 6.41 -$20.25M -$48.27 N/A

Is ATHX or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Vaccinex N/A N/A -383.58%

Do analysts prefer NXTS or ATHX?

Given Athersys' higher possible upside, analysts clearly believe Athersys is more favorable than Nexentis Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXTS or ATHX more profitable?

Athersys' return on equity of 0.00% beat Nexentis Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Nexentis Technologies N/A -145.15% -111.82% Athersys N/A N/A -223.03%

Do analysts recommend JUNS or ATHX?

Given Athersys' higher probable upside, analysts plainly believe Athersys is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is JUNS or ATHX more profitable?

Athersys' return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A -1,314.62% -228.63% Athersys N/A N/A -223.03%

Do analysts recommend GRI or ATHX?

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,354.55%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than Athersys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GRI or ATHX more profitable?

Athersys' return on equity of 0.00% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% Athersys N/A N/A -223.03%

Athersys (ATHX) Competitors

Compare

ATHX vs. SXTP, VCNX, NXTS, JUNS, and GRI

Should you buy Athersys stock or one of its competitors? Athersys's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTP), Vaccinex (VCNX), Nexentis Technologies (NXTS), Jupiter Neurosciences (JUNS), and GRI Bio (GRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athersys compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Athersys. 60 Degrees Pharmaceuticals' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Neutral
Athersys	Neutral

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

60 Degrees Pharmaceuticals has higher revenue and earnings than Athersys. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.13	-$7.36M	-$8.92	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

Athersys has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Athersys	N/A	N/A	-223.03%

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 1,125.66%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

60 Degrees Pharmaceuticals beats Athersys on 9 of the 12 factors compared between the two stocks.

How does Athersys compare to Vaccinex?

Athersys (NASDAQ:ATHX) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Vaccinex	N/A	N/A	-383.58%

Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

In the previous week, Vaccinex had 1 more articles in the media than Athersys. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for Athersys. Athersys' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Vaccinex	Neutral

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Vaccinex	$388K	6.41	-$20.25M	-$48.27	N/A

19.4% of Athersys shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Vaccinex beats Athersys on 6 of the 9 factors compared between the two stocks.

How does Athersys compare to Nexentis Technologies?

Nexentis Technologies (NASDAQ:NXTS) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Nexentis Technologies has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market.

Given Athersys' higher possible upside, analysts clearly believe Athersys is more favorable than Nexentis Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nexentis Technologies has higher revenue and earnings than Athersys. Nexentis Technologies is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	$210K	13.05	-$4M	-$114.15	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

In the previous week, Nexentis Technologies had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for Nexentis Technologies and 0 mentions for Athersys. Nexentis Technologies' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company	Overall Sentiment
Nexentis Technologies	Neutral
Athersys	Neutral

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by company insiders. Comparatively, 0.0% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Athersys' return on equity of 0.00% beat Nexentis Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-145.15%	-111.82%
Athersys	N/A	N/A	-223.03%

Summary

Nexentis Technologies beats Athersys on 8 of the 11 factors compared between the two stocks.

How does Athersys compare to Jupiter Neurosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Jupiter Neurosciences has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

19.4% of Athersys shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Given Athersys' higher probable upside, analysts plainly believe Athersys is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Athersys' return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
Athersys	N/A	N/A	-223.03%

Jupiter Neurosciences has higher earnings, but lower revenue than Athersys. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	112.80	-$8.65M	-$20.30	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

In the previous week, Jupiter Neurosciences had 6 more articles in the media than Athersys. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 0 mentions for Athersys. Jupiter Neurosciences' average media sentiment score of 0.11 beat Athersys' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jupiter Neurosciences	Neutral
Athersys	Neutral

Summary

Jupiter Neurosciences and Athersys tied by winning 6 of the 12 factors compared between the two stocks.

How does Athersys compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 0.0% of Athersys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,354.55%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GRI Bio has higher earnings, but lower revenue than Athersys. GRI Bio is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

Athersys' return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
Athersys	N/A	N/A	-223.03%

GRI Bio has a beta of -1.21, meaning that its share price is 221% less volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

In the previous week, GRI Bio had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for GRI Bio and 0 mentions for Athersys. GRI Bio's average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company	Overall Sentiment
GRI Bio	Neutral
Athersys	Neutral

Summary

GRI Bio beats Athersys on 8 of the 12 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHX vs. The Competition

Export

Metric	Athersys	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$833K	$11.87B	$6.99B	$12.83B
Dividend Yield	N/A	2.69%	2.58%	10.06%
P/E Ratio	0.00	783.49	268.64	24.76
Price / Sales	N/A	748.15	585.15	95.42
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	N/A	10.16	11.31	6.45
Net Income	-$72.53M	$2.78B	$3.44B	$347.05M

Athersys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHX Athersys	N/A	N/A	N/A	N/A	$833K	$146K	N/A	24
SXTP 60 Degrees Pharmaceuticals	2.5137 of 5 stars	$1.19 -2.9%	$13.85 +1,068.8%	-79.7%	$3.15M	$1.41M	N/A	3	News Coverage Upcoming Earnings
VCNX Vaccinex	N/A	$1.12 flat	N/A	+41.4%	$2.91M	$388K	N/A	40
NXTS Nexentis Technologies	0.474 of 5 stars	$1.96 +6.1%	N/A	-96.9%	$2.86M	$210K	N/A	2	Short Interest Increase Gap Up
JUNS Jupiter Neurosciences	0.8989 of 5 stars	$0.07 -4.2%	N/A	-94.1%	$2.67M	$40.45K	N/A	5	Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHX) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athersys (ATHX) Competitors

ATHX vs. SXTP, VCNX, NXTS, JUNS, and GRI

How does Athersys compare to 60 Degrees Pharmaceuticals?

Summary

How does Athersys compare to Vaccinex?

Summary

How does Athersys compare to Nexentis Technologies?

Summary

How does Athersys compare to Jupiter Neurosciences?

Summary

How does Athersys compare to GRI Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athersys (ATHX) Competitors

ATHX vs. SXTP, VCNX, NXTS, JUNS, and GRI

How does Athersys compare to 60 Degrees Pharmaceuticals?

Which has more volatility and risk, SXTP or ATHX?

Does the media favor SXTP or ATHX?

Do institutionals & insiders have more ownership in SXTP or ATHX?

Which has better valuation & earnings, SXTP or ATHX?

Is SXTP or ATHX more profitable?

Do analysts rate SXTP or ATHX?

Summary

How does Athersys compare to Vaccinex?

Is ATHX or VCNX more profitable?

Which has more volatility and risk, ATHX or VCNX?

Does the media favor ATHX or VCNX?

Which has preferable valuation and earnings, ATHX or VCNX?

Do institutionals and insiders have more ownership in ATHX or VCNX?

Summary

How does Athersys compare to Nexentis Technologies?

Which has more risk and volatility, NXTS or ATHX?

Do analysts prefer NXTS or ATHX?

Which has higher valuation & earnings, NXTS or ATHX?

Does the media favor NXTS or ATHX?

Do insiders & institutionals have more ownership in NXTS or ATHX?

Is NXTS or ATHX more profitable?

Summary

How does Athersys compare to Jupiter Neurosciences?

Which has more volatility & risk, JUNS or ATHX?

Do insiders and institutionals believe in JUNS or ATHX?

Do analysts recommend JUNS or ATHX?

Is JUNS or ATHX more profitable?

Which has preferable earnings & valuation, JUNS or ATHX?

Does the media favor JUNS or ATHX?

Summary

How does Athersys compare to GRI Bio?

Do institutionals & insiders believe in GRI or ATHX?

Do analysts recommend GRI or ATHX?

Which has stronger valuation & earnings, GRI or ATHX?

Is GRI or ATHX more profitable?

Which has more volatility and risk, GRI or ATHX?

Does the media favor GRI or ATHX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools